When was MapLight founded?

MapLight was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is MapLight located?

MapLight is headquartered in Redwood City, United States. It is registered at Concord, Massachusetts.

Who is the current CEO of MapLight?

Christopher Kroeger and Chris Kroeger s of MapLight. Christopher Kroeger has also founded 1 company.

How many employees does MapLight have?

As of Aug 31, 2026, the latest employee count at MapLight is 157.

Is MapLight a funded company?

MapLight is a funded company, having raised a total of $698M across 8 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 22, 2019.

When was the latest funding round of MapLight?

MapLight's latest funding was a $***** Post IPO round on Aug 13, 2026, with participation from 0 investor.

Where does MapLight rank among its competitors?

MapLight ranks 24th amongst 2863 active competitors, of which 974 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of MapLight?

MapLight's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

MapLight - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutic for central nervous system disorders. The company's flagship product ML-004 helps in treating mental disorders, Alzheimer's agitation, and others. It has also developed ML-007, ML-009 for treating dyskinesia, schizophrenia, and ML-016 for treating anhedonia.

Website: maplightrx.com
Social
Email ID: *****@maplightrx.com
Registered Address: Concord, Massachusetts

Key Metrics

Founded Year

2018

Location

Redwood City, United States

Stage

Public

Total Funding

$698M in 8 rounds

Latest Funding Round

Post IPO, Aug 13, 2026, $*****

Investors

Goldman Sachs & 11 more

Ranked

24^th among 2863 active competitors

Employee Count

157 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 578 more

Exit Details

Public

View MapLight's full profile

MapLight is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MAPLIGHT THERAPEUTICS, INC. CIN: 832163243 , United States, Active	Dec 31, 1999	-	63 (As on Dec 31, 2024)	-

MapLight got listed on Oct 27, 2025.

Click here to take a look at MapLight's IPO in detail

MapLight has raised a total funding of $698M over 8 rounds. Its first funding round was on Feb 22, 2019. MapLight has 12 institutional investors.

Here is the list of recent funding rounds of MapLight:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 13, 2026	2534601	Post IPO	4131270	6847604	6852687	6642872
Jul 18, 2025	4820649	Series D	8059255	7558129	6176970	Sanofi Ventures & 5 more
Oct 30, 2023	7307700	Series C	6176222	9199387	Novo Holdings & 2 more	8956724

Access funding benchmarks and valuations. Sign up today!

View details of MapLight's funding rounds and investors

The founders of MapLight are Christopher Kroeger and Chris Kroeger. Chris Kroeger and Christopher Kroeger are the CEOs of MapLight.

Here are the details of MapLight's key team members:

Christopher Kroeger: Founder & CEO of MapLight.
Chris Kroeger: Founder & CEO of MapLight.

View details of MapLight's Founder profiles and Board Members

MapLight's employee count trend

MapLight has 157 employees as of Aug 26. Here is MapLight's employee count trend over the years:

Uncover MapLight's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MapLight include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of MapLight, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
24th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	T. Rowe Price, Goldman Sachs & 10 others	68/100